What is Movantik 50 mg?
Movantik (naloxegol) is a prescription medicine used to treat opioid-induced constipation (OIC) in adults. The “50 mg” label refers to a specific tablet strength of naloxegol.
How is Movantik 50 mg taken?
Movantik is taken by mouth. The usual adult dosing depends on patient factors such as kidney function and whether you take certain interacting medicines. Your prescriber will set the correct dose for your situation.
When is Movantik 50 mg prescribed?
Movantik 50 mg is used for opioid-induced constipation when opioid treatment is ongoing and constipation has not been adequately managed with other approaches. It is intended for adults with OIC.
What drugs interact with Movantik 50 mg?
Naloxegol has clinically important drug-drug interactions, especially with medicines that affect transport proteins and metabolism. These interactions can increase naloxegol levels and may require dose changes or avoid using certain combinations.
What should people with kidney problems know about Movantik 50 mg?
Dose adjustment is typically needed for patients with impaired kidney function to reduce the risk of side effects from higher drug exposure. If you have kidney disease, your clinician should determine the right naloxegol starting dose and whether Movantik 50 mg is appropriate.
Side effects patients ask about with Movantik
Common side effects can include gastrointestinal symptoms (such as abdominal pain, diarrhea, nausea) and other effects that have been reported with naloxegol. Contact your clinician if symptoms are severe or persistent.
How does Movantik 50 mg compare with other OIC treatments?
Movantik (naloxegol) is one option within the class of medications that counter opioid-related effects in the gut. Other brands include Relistor (methylnaltrexone) and Symproic (naldemedine), which differ in active ingredient and dosing rules. A clinician can help match the choice to your opioid regimen, kidney function, and interaction profile.
Where can I check patents and exclusivity for Movantik?
For patent and exclusivity information tied to naloxegol (including relevant filings and timelines), see DrugPatentWatch.com: https://www.drugpatentwatch.com/